Skip to content
DraconiticResearch
Search Sources API
194,230 studies31 sourcesUpdated 56 min ago
PreprintCC BYbioRxiv

Stochastic Boolean Model of Death Signaling in MCF7:5C Predicts Cell Death Inducers and Inhibitors

  1. 1Division of Systems Biology, Academy of Integrated Science, Virginia Polytechnic Institute and State University, Blacksburg, VA 24961, USA

Abstract

Disrupted cell death signaling contributes significantly to the inappropriate survival of cancer cells, enabling them to evade the apoptotic processes that normally eliminate damaged or abnormal cells. To assess the impact of disrupted cell death signaling on cancer cell survival, we developed a continuous-time stochastic Boolean model of apoptosis signaling in MCF7:5C human breast cancer cells that are resistant to estrogen deprivation and undergo apoptosis in response to estrogen. The model was calibrated to replicate the dynamics of key apoptosis regulators in MCF7:5C cells before and after 17{beta}-estradiol (E2) treatment. Subsequently, the calibrated model was used to predict both the single and double perturbations that inhibit cell death in estradiol-treated MCF7:5C cells, and additional single interventions capable of reinducing apoptosis. For example, strains with single-gene deletion of PERK, eIF2, CHOP, or ATF4 enabled E2-treated MCF7:5C cells to evade apoptosis. However, additional inhibition of SRC, PI3K, ESR1, CEBPB, or MAPK8 restored apoptotic responses in these resistant cells. We identified 30 resistant cell strains with double mutations and 506 drug-target combinations capable of inducing four distinct modes of cell death: direct CASP7 activation, extrinsic apoptosis, intrinsic apoptosis, and combined intrinsic/extrinsic apoptosis. Overall, our model successfully explains the drug response behavior of MCF7:5C cells, predicts mechanisms of drug resistance, and suggests treatment strategies to overcome this resistance.

Related

  1. Cell Viability of the Administered Product Predicts Response to Stromal Vascular Fraction in Patients with Erectile Dysfunction Unresponsive to Phosphodiesterase Type 5 Inhibitors
    Ahmet Semih Güleser, Atakan Eren, Fatih Altunrende +2
    Medicina (Kaunas, Lithuania)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. N6-Substituted adenosine analogues, a novel class of JAK2 inhibitors, potently block STAT3 signaling in human cancer cells
    Peng Liu, Liwei Zhao, Ximing Xu +8
    Cancer LettersPeer-reviewedCC BY-NC10 citedOncologyHAL
  3. Programmed Remote Cyano Migration Yields Cyanamides as Potent Ferroptosis Inducers
    Peng Xu, Zhijie Deng
    ACS Central SciencePeer-reviewedCC BY 4.0Full textGeneral medicineCrossref
  4. Synthetic inhibitors of pregnancy-associated plasma protein-A regulate IGF-1 signaling in vitro and in vivo
    A. Kertisova, S.-W. Shih, N. S. Kirk +10
    bioRxivPreprintCC BY-NCFull textEndocrinology & metabolismbioRxiv
  5. Trial-reported arthralgia of androgen deprivation therapy plus androgen receptor signaling inhibitors in prostate cancer: evidence from phase III randomized trials
    Zhenping Han, Jing Tian, Zhuangcheng Huang +6
    BMC CancerPeer-reviewedCC BY-NC-ND 4.0Full textGeneral medicinePMC
BibTeX
@misc{taoma2026stochastic,
  title = {{Stochastic Boolean Model of Death Signaling in MCF7:5C Predicts Cell Death Inducers and Inhibitors}},
  author = {K. Taoma and T. Laomettachit and S. Sengupta and Y. Wang and R. Clarke and P. Kraikivski},
  howpublished = {bioRxiv},
  year = {2026},
  month = sep,
  doi = {10.64898/2026.09.05.749284},
  url = {https://www.biorxiv.org/content/10.64898/2026.09.05.749284v1},
  note = {CC BY},
}
RIS
TY  - UNPB
TI  - Stochastic Boolean Model of Death Signaling in MCF7:5C Predicts Cell Death Inducers and Inhibitors
AU  - K. Taoma
AU  - T. Laomettachit
AU  - S. Sengupta
AU  - Y. Wang
AU  - R. Clarke
AU  - P. Kraikivski
PY  - 2026
DA  - 2026/09/05
PB  - bioRxiv
DO  - 10.64898/2026.09.05.749284
UR  - https://www.biorxiv.org/content/10.64898/2026.09.05.749284v1
AB  - Disrupted cell death signaling contributes significantly to the inappropriate survival of cancer cells, enabling them to evade the apoptotic processes that normally eliminate damaged or abnormal cells. To assess the impact of disrupted cell death signaling on cancer cell survival, we developed a continuous-time stochastic Boolean model of apoptosis signaling in MCF7:5C human breast cancer cells that are resistant to estrogen deprivation and undergo apoptosis in response to estrogen. The model was calibrated to replicate the dynamics of key apoptosis regulators in MCF7:5C cells before and after 17{beta}-estradiol (E2) treatment. Subsequently, the calibrated model was used to predict both the single and double perturbations that inhibit cell death in estradiol-treated MCF7:5C cells, and additional single interventions capable of reinducing apoptosis. For example, strains with single-gene deletion of PERK, eIF2, CHOP, or ATF4 enabled E2-treated MCF7:5C cells to evade apoptosis. However, additional inhibition of SRC, PI3K, ESR1, CEBPB, or MAPK8 restored apoptotic responses in these resistant cells. We identified 30 resistant cell strains with double mutations and 506 drug-target combinations capable of inducing four distinct modes of cell death: direct CASP7 activation, extrinsic apoptosis, intrinsic apoptosis, and combined intrinsic/extrinsic apoptosis. Overall, our model successfully explains the drug response behavior of MCF7:5C cells, predicts mechanisms of drug resistance, and suggests treatment strategies to overcome this resistance.
ER  -